A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

Abstract

Selegiline was safe and well tolerated by HIV-infected individuals with cognitive impairment and mild to moderate immune suppression; however, no cognitive or functional improvement was observed in this phase II study.

Minocycline treatment for HIV-associated cognitive impairment

“…At each visit, participants were assessed for adverse clinical events. A neurologic examination and safety laboratory tests including serum chemistry profiles, hematology, CD4ϩ T-lymphocyte counts, and plasma HIV RNA levels were performed at screening and weeks 4,12 26 Secondary outcome measures of efficacy included the Global Deficit Score, 27,28 performance on individual neuropsychological tests, changes in neuropsychological test z scores grouped by cognitive domains, changes in individual subjective and functional performance assessments, and changes in the Investigator and Subject Clinical Global Impressions. 26 Primary measures of safety included the frequency of adverse events and abnormal results on laboratory tests, and changes over time in vital signs and laboratory tests.…”

Evidence-based perspectives on the implementation of screening for neurocognitive impairment in HIV

“…Trials of adjunctive pharmacological treatment, including minocycline, selegiline, valproate, rivastigmine, and lithium, [82][83][84][85][86] have not shown benefits in cognitive function in PLWH. It may be that the trials were underpowered or too short in duration to show benefit, or that too heterogeneous a group of patients was targeted.…”

ASHP Guidelines on Pharmacist Involvement in HIV Care

“…101 This prolonged inflammatory state may lead to the generation of free radicals and oxidative stress in various organs. 102 Another possible mechanism is via a hypercoagulable state that is seen in patients with HIV. Evidence supports a depletion of proteins C and S, leading to enhanced thrombosis and subsequent disease complications.…”